Samsung Biologics has reached an agreement with Biogen for the buyout of Biogen’s stake in the Samsung Bioepis joint venture for $2.3 billion. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis, fully capitalizing on Samsung Bioepis’ growth outlook. The board of directors of Samsung Biologics has approved the transaction, in which payment for the shares will be made in installments over the next two years, and full ownership will take effect at t...